A new trading day began on Friday, with Intellia Therapeutics Inc (NASDAQ: NTLA) stock price down -1.93% from the previous day of trading, before settling in for the closing price of $8.28. NTLA’s price has ranged from $5.90 to $28.18 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 15.68%. Meanwhile, its annual earnings per share averaged 19.21%. With a float of $97.49 million, this company’s outstanding shares have now reached $103.54 million.
Let’s determine the extent of company efficiency that accounts for 403 employees. In terms of profitability, gross margin is 86.74%, operating margin of -923.1%, and the pretax margin is -896.77%.
Intellia Therapeutics Inc (NTLA) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Intellia Therapeutics Inc is 5.88%, while institutional ownership is 90.96%. The most recent insider transaction that took place on Apr 29 ’25, was worth 2,252. In this transaction Director of this company sold 265 shares at a rate of $8.50, taking the stock ownership to the 19,203 shares. Before that another transaction happened on Mar 04 ’25, when Company’s EVP, Chief Technical Officer sold 679 for $8.99, making the entire transaction worth $6,104. This insider now owns 95,369 shares in total.
Intellia Therapeutics Inc (NTLA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 19.21% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 27.77% during the next five years compared to -20.04% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Here are Intellia Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 18.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.23, a number that is poised to hit -1.04 in the next quarter and is forecasted to reach -3.90 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Looking closely at Intellia Therapeutics Inc (NASDAQ: NTLA), its last 5-days average volume was 4.21 million, which is a jump from its year-to-date volume of 3.41 million. As of the previous 9 days, the stock’s Stochastic %D was 33.35%. Additionally, its Average True Range was 0.70.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 28.14%, which indicates a significant decrease from 44.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 98.72% in the past 14 days, which was higher than the 86.39% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.29, while its 200-day Moving Average is $14.51. However, in the short run, Intellia Therapeutics Inc’s stock first resistance to watch stands at $8.53. Second resistance stands at $8.95. The third major resistance level sits at $9.19. If the price goes on to break the first support level at $7.88, it is likely to go to the next support level at $7.64. Should the price break the second support level, the third support level stands at $7.22.
Intellia Therapeutics Inc (NASDAQ: NTLA) Key Stats
With a market capitalization of 841.07 million, the company has a total of 103,583K Shares Outstanding. Currently, annual sales are 57,880 K while annual income is -519,020 K. The company’s previous quarter sales were 12,870 K while its latest quarter income was -128,900 K.
